Kennedy Capital Management, Inc. Geron Corp Transaction History

Kennedy Capital Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.1 - $5.09 $3.31 Million - $5.43 Million	-1,066,580 Reduced 94.78%	58,700 $248,000
Q1 2024 May 15, 2024	SELL	$1.75 - $3.44 $17,351 - $34,107	-9,915 Reduced 0.87%	1,125,280 $3.71 Million
Q4 2023 Feb 14, 2024	BUY	$1.74 - $2.31 $1.98 Million - $2.62 Million	1,135,195 New	1,135,195 $2.4 Million
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $72,720 - $86,691	-35,823 Reduced 2.87%	1,210,418 $2.93 Million
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $2.08 Million - $3.66 Million	1,246,241 New	1,246,241 $2.92 Million

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.54B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.